Literature DB >> 16120947

Role of N-terminal pro-B-type natriuretic peptide in risk stratification in patients presenting in the emergency room.

Martin Möckel1, Reinhold Müller, Jörn O Vollert, Christian Müller, Angelika Carl, Dirk Peetz, Felix Post, J Klaus Kohse, Karl J Lackner.   

Abstract

BACKGROUND: Natriuretic peptides are promising markers in diagnosing acute and chronic heart failure and assessing prognosis in these patients. Increasing routine use to unselected patients is challenged by false-positive results. The aims of this study were to assess (a) the distributions of N-terminal B-type natriuretic peptide (NT-proBNP) values in various diagnostic groups, (b) factors that influence NT-proBNP, and (c) the value of NT-proBNP in risk stratification in unselected emergency room (ER) patients.
METHODS: NT-proBNP was measured in 876 unselected consecutive patients [mean (SD) age, 58 (18) years; 53% male] attending the ERs of 2 university hospitals and 1 community hospital. Diagnoses, age, sex, hemoglobin, creatinine (CREA), C-reactive protein (CRP), troponin T, and intensity of care were documented. In a subset consisting of all 417 patients at 1 center, in-hospital follow-up was completed with respect to a complicated clinical course, including intensive care treatment and death.
RESULTS: NT-proBNP was significantly increased in patients with cardiac diagnoses or histories compared with patients with only pulmonary or other diagnoses. In patients with other diagnoses, NT-proBNP values increased significantly with the number of atherosclerotic risk factors (P=0.044). Age, renal function, CRP, and to a much lesser extent, hemoglobin significantly influenced NT-proBNP values. The amount of care was positively correlated with NT-proBNP (P<0.001). Classification and regression tree analysis showed a superior impact of NT-proBNP for identification of high-risk patients.
CONCLUSIONS: NT-proBNP is a promising marker for identification of patients with structural heart disease in the ER and a suitable tool for risk stratification. Its use in the ER should be limited to clearly clinically defined patient groups at present to avoid a potential excess of additional diagnostic procedures in positive but asymptomatic patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16120947     DOI: 10.1373/clinchem.2005.049155

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  4 in total

Review 1.  Anti-inflammatory therapeutics for the treatment of atherosclerosis.

Authors:  Israel F Charo; Rebecca Taub
Journal:  Nat Rev Drug Discov       Date:  2011-05       Impact factor: 84.694

2.  Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II).

Authors:  M Möckel; R Müller; J O Vollert; C Müller; O Danne; R Gareis; T Störk; R Dietz; W Koenig
Journal:  Clin Res Cardiol       Date:  2007-06-27       Impact factor: 5.460

3.  N-terminal pro brain natriuretic peptide in coronary artery disease.

Authors:  Sim Sai Tin; Viroj Wiwanitkit
Journal:  J Saudi Heart Assoc       Date:  2014-12-30

4.  Plasma B-type natriuretic peptide levels are poorly related to the occurrence of ischemia or ventricular arrhythmias during symptom-limited exercise in low-risk patients.

Authors:  Andreu Porta; José A Barrabés; Jaume Candell-Riera; Luis Agulló; Santiago Aguadé-Bruix; Gustavo de León; Jaume Figueras; David Garcia-Dorado
Journal:  Arch Med Sci       Date:  2016-04-12       Impact factor: 3.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.